Skip to main content
. Author manuscript; available in PMC: 2017 Mar 30.
Published in final edited form as: Neurourol Urodyn. 2011 May 11;30(7):1319–1324. doi: 10.1002/nau.21028

Table I. Subjective and Objective Measures in the BE-DRI study at Baseline, 10 Weeks, and 8 Months.

Baseline (n=307) 10 weeksΔ (n=272) 8 monthsΔ (n=241)
Subjective Measures (Mean ± SD)
 • UDI (range 0-300) 120.5±49.6 54.1±43.4 72.7±50.4
 • UDI Irritative (range 0-100) 58.4±21.8 26.4±22.9 36.5±25.6
 • IIQ (range 0-400) 153.6±99.5 68.9±78.9 78.9±85.5
 • OAB-q (HRQL) (range 25-150) 61.7±24.1 85.6±15.7 81.2±19.3
 • OAB-q (SS) (range 8-48) 60.2±20.9 26.9±19.3 34.2±22.4
Objective Measures (Mean ± SD)
 • Incontinence Episodes(IE) per day 3.7±2.4 0.9±1.2 1.4±1.9
*

Health-related quality of life subscale; higher score represents improved quality of life. For all other measures a lower score/value is indicative of a reduction in bother, symptom severity and incontinence episodes.

Δ

P values all < 0.0001.